vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v21i5.2452vsp-3030Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWДефект филаггрина при атопическом дерматите: современные методы коррекцииFilaggrin Defect at Atopic Dermatitis: Modern Treatment Optionshttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич - доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей, профессор кафедры дерматовенерологии и косметологии ЦГМА, профессор кафедры педиатрии и детской ревматологии ФГАОУ ВО Первый МГМУ им. И.М. Сеченова (Сеченовский Университет).

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1,  тел.: +7 (495) 967-14-20

Moscow

m_nn2001@mail.ruhttps://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

Москва

Moscow

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

Москва

Moscow

https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.

Москва

Moscow

https://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchianEduard T.

Москва

Moscow

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва

Moscow

https://orcid.org/0000-0001-6884-5171СавеловаА. А.SavelovaAlena A.

Москва

Moscow

https://orcid.org/0000-0002-2922-3924НежведиловаР. Ю.NezhvedilovaRoza Y.

Москва

Moscow

https://orcid.org/0000-0003-4297-4631РусаковаЛ. Л.RusakovaLyudmila L.

Москва

Moscow

НМИЦ здоровья детей; Первый МГМУ им. И.М. Сеченова (Сеченовский Университет); ЦГМА Управления делами Президента РФРоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential AffairsRussian FederationНМИЦ здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ РНЦХ им. акад. Б.В. ПетровскогоРоссияPediatrics and Child Health Research Institute in Petrovsky National Research Centre of SurgeryRussian Federation202207112022215347351Copyright © Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., Савелова А.А., Нежведилова Р.Ю., Русакова Л.Л., 20222022Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., Савелова А.А., Нежведилова Р.Ю., Русакова Л.Л.Murashkin N.N., Opryatin L.A., Epishev R.V., Materikin A.I., Ambarchian E.T., Ivanov R.A., Savelova A.A., Nezhvedilova R.Y., Rusakova L.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3030

Атопический дерматит — распространенное хроническое заболевание кожи, патогенез которого во многом обусловлен врожденным или приобретенным дефицитом белка филаггрина. В последние годы получено большое количество данных о причинах дефицита филаггрина. Описаны структура и функции этого белка, что открывает новые возможности терапии атопического дерматита.

Atopic dermatitis is a common chronic skin disease, its pathogenesis is associated with congenital or acquired deficiency of filaggrin protein. In recent years, extensive evidence on the causes of filaggrin deficiency has been obtained. The structure and functions of this protein are described, that opens new approaches for atopic dermatitis management.

атопический дерматиткожный барьерфилаггринэмолентыфилагринолatopic dermatitisskin barrierfilaggrinemollientsfilagrinolОтсутствуетNot specifiedReferencesАтопический дерматит: клинические рекомендации. — 2020. Доступно по: https://nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf. Ссылка активна на 24.09.2022.Atopicheskii dermatit: Clinical guidelines. (In Russ). Доступно по: https://nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf. Ссылка активна на 24.09.2022.Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):214–227. doi: https://doi.org/10.11613/bm.2019.0205Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):214–227. doi: https://doi.org/10.11613/bm.2019.0205Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications. J Dermatol. 2014;41(3):205–212. doi: https://doi.org/10.1111/1346-8138.12317Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications. J Dermatol. 2014;41(3):205–212. doi: https://doi.org/10.1111/1346-8138.12317Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in Atopic Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):113–122. doi: https://doi.org/10.1016/j.iac.2016.08.007Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in Atopic Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):113–122. doi: https://doi.org/10.1016/j.iac.2016.08.007Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792–799. doi: https://doi.org/10.1016/j.jaci.2014.06.014Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792–799. doi: https://doi.org/10.1016/j.jaci.2014.06.014Dale BA, Presland RB, Lewis SP, et al. Transient Expression of Epidermal Filaggrin in Cultured Cells Causes Collapse of Intermed iate Filament Networks with Alteration of Cell Shape and Nuclear Integrity. J Invest Dermatol. 1997;108(2):179–187. doi: https://doi.org/10.1111/1523-1747.ep12334205Dale BA, Presland RB, Lewis SP, et al. Transient Expression of Epidermal Filaggrin in Cultured Cells Causes Collapse of Intermed iate Filament Networks with Alteration of Cell Shape and Nuclear Integrity. J Invest Dermatol. 1997;108(2):179–187. doi: https://doi.org/10.1111/1523-1747.ep12334205Stout TE, McFarland T, Mitchell JC, et al. Recombinant filaggrin is internalized and processed to correct filaggrin deficiency. J Invest Derm at ol. 2014;134(2):423–429. doi: https://doi.org/10.1038/jid.2013.284Stout TE, McFarland T, Mitchell JC, et al. Recombinant filaggrin is in- ternalized and processed to correct filaggrin deficiency. J Invest Derm at ol. 2014;134(2):423–429. doi: https://doi.org/10.1038/jid.2013.284McAleer MA, Jakasa I, Raj N, et al. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. Br J Dermatol. 2018;179(2):431–441. doi: https://doi.org/10.1111/bjd.16691McAleer MA, Jakasa I, Raj N, et al. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. Br J Dermatol. 2018;179(2):431–441. doi: https://doi.org/10.1111/bjd.16691Garrett JP, Hoffstad O, Apter AJ, Margolis DJ. Racial comparison of filaggrin null mutations in asthmatic patients with atopic dermatitis in a US population. J Allergy Clin Immunol. 2013;132(5): 1232–1234. doi: https://doi.org/10.1016/j.jaci.2013.07.005Garrett JP, Hoffstad O, Apter AJ, Margolis DJ. Racial comparison of filaggrin null mutations in asthmatic patients with atopic dermatitis in a US population. J Allergy Clin Immunol. 2013;132(5): 1232–1234. doi: https://doi.org/10.1016/j.jaci.2013.07.005Brough HA, Simpson A, Makinson K, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-offunction mutations. J Allergy Clin Immunol. 2014;134(4):867–875. doi: https://doi.org/10.1016/j.jaci.2014.08.011Brough HA, Simpson A, Makinson K, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-offunction mutations. J Allergy Clin Immunol. 2014;134(4):867–875. doi: https://doi.org/10.1016/j.jaci.2014.08.011Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387: 1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-XWeidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387: 1109–1122. doi: https://doi.org/10.1016/S0140-6736(15)00149-XIrvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011, 365(14): 1315–1327. doi: https://doi.org/10.1056/NEJMra1011040Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011, 365(14): 1315–1327. doi: https://doi.org/10.1056/NEJMra1011040Brauweiler AM, Bin L, Kim BE, et al. Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal a-toxin-induced keratinocyte death. J Allergy Clin Immunol. 2013;131:421–427. e1–e2. doi: https://doi.org/10.1016/j.jaci.2012.10.030Brauweiler AM, Bin L, Kim BE, et al. Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal a-toxin-induced keratinocyte death. J Allergy Clin Immunol. 2013;131:421–427. e1–e2. doi: https://doi.org/10.1016/j.jaci.2012.10.030Seltmann J, Roesner LM, von Hesler FW, et al. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol. 2015;135(6):1659–1661. doi: https://doi.org/10.1016/j.jaci.2015.01.048Seltmann J, Roesner LM, von Hesler FW, et al. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol. 2015;135(6):1659–1661. doi: https://doi.org/10.1016/j.jaci.2015.01.048Kim BE, Bin L, Ye YM, et al. IL-25 enhances HSV-1 replication by inhibiting filaggrin expression, and acts synergistically with Th2 cytokines to enhance HSV-1 replication. J Invest Dermatol. 2013;133:2678–2685. doi: https://doi.org/10.1038/jid.2013.223Kim BE, Bin L, Ye YM, et al. IL-25 enhances HSV-1 replication by inhibiting filaggrin expression, and acts synergistically with Th2 cytokines to enhance HSV-1 replication. J Invest Dermatol. 2013;133:2678–2685. doi: https://doi.org/10.1038/jid.2013.223Kim JH, Bae HC, Ko NY, et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol. 2015;136(1):205–208.e9. doi: https://doi.org/10.1016/j.jaci.2015.04.026Kim JH, Bae HC, Ko NY, et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol. 2015;136(1):205–208.e9. doi: https://doi.org/10.1016/j.jaci.2015.04.026Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–677.e7. doi: https://doi.org/10.1016/j.jaci.2015.03.051Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–677.e7. doi: https://doi.org/10.1016/j.jaci.2015.03.051Wollenberg A, Ehmann LM. Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema. Ann Dermatol. 2012;24(3):253. doi: https://doi.org/10.5021/ad.2012.24.3.253Wollenberg A, Ehmann LM. Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema. Ann Dermatol. 2012;24(3):253. doi: https://doi.org/10.5021/ad.2012.24.3.253Amat F, Soria A, Tallon P, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: An overview. Clin Exp Allergy. 2018;48(8):919–934. doi: https://doi.org/10.1111/cea.13156Amat F, Soria A, Tallon P, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: An overview. Clin Exp Allergy. 2018;48(8):919–934. doi: https://doi.org/10.1111/cea.13156Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: https://doi.org/10.1111/jdv.14891Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: https://doi.org/10.1111/jdv.14891Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–358. doi: https://doi.org/10.1016/j.jaci.2016.06.002Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–358. doi: https://doi.org/10.1016/j.jaci.2016.06.002Man MQ, Barish GD, Schmuth M, et al. Deficiency of PPARbeta/ delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol. 2008;128(2):370–377. doi: https://doi.org/10.1038/sj.jid.5701026Man MQ, Barish GD, Schmuth M, et al. Deficiency of PPARbeta/ delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol. 2008;128(2):370–377. doi: https://doi.org/10.1038/sj.jid.5701026Granato L. Modulator from fractions of vegetable unsaponifiables. Personal Care. 2012;09:69–72.Granato L. Modulator from fractions of vegetable unsaponifiables. Personal Care. 2012;09:69–72.

The authors declare that there are no conflicts of interest present.